Literature DB >> 9197277

Increased A beta 42(43)-plaque deposition in early-onset familial Alzheimer's disease brains with the deletion of exon 9 and the missense point mutation (H163R) in the PS-1 gene.

K Ishii1, K Ii, T Hasegawa, S Shoji, A Doi, H Mori.   

Abstract

Cerebral amyloid deposition is a neuropathological hallmark for Alzheimer's disease (AD). Immunohistochemical analysis of two A beta species (A beta 42/43 and A beta 40) deposition was undertaken using the carboxyl end-specific antibodies to determine the molecular alteration of these species in the brains of patients whose presenilin 1 (PS-1) gene, the major causative gene for the early-onset familial AD, bears the point mutation (H163R) and the deletion of exon 9. We found a marked increase in A beta 42-plaque deposition in brains of patients with PS-1 mutations compared with that in brains of those with sporadic AD. The results of immunohistochemical analysis indicate that both mutation and deletion in the PS-1 gene promote deposition of A beta 42-plaques indicating the pathological association of PS-1 and betaAPP/A beta 42 in early-onset familial AD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9197277     DOI: 10.1016/s0304-3940(97)00347-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease.

Authors:  D M Mann; S M Pickering-Brown; A Takeuchi; T Iwatsubo
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

Review 2.  Novel approaches to models of Alzheimer's disease pathology for drug screening and development.

Authors:  Laura Shaughnessy; Beth Chamblin; Lori McMahon; Ayyappan Nair; Mary Beth Thomas; John Wakefield; Frank Koentgen; Ram Ramabhadran
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

3.  Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.

Authors:  Randall J Bateman; Paul S Aisen; Bart De Strooper; Nick C Fox; Cynthia A Lemere; John M Ringman; Stephen Salloway; Reisa A Sperling; Manfred Windisch; Chengjie Xiong
Journal:  Alzheimers Res Ther       Date:  2011-01-06       Impact factor: 6.982

4.  β-Secretases, Alzheimer's Disease, and Down Syndrome.

Authors:  Robin L Webb; M Paul Murphy
Journal:  Curr Gerontol Geriatr Res       Date:  2012-02-28

Review 5.  Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene.

Authors:  A J Larner; M Doran
Journal:  J Neurol       Date:  2005-11-04       Impact factor: 6.682

Review 6.  Reactive astrocytes as treatment targets in Alzheimer's disease-Systematic review of studies using the APPswePS1dE9 mouse model.

Authors:  Tamar Smit; Natasja A C Deshayes; David R Borchelt; Willem Kamphuis; Jinte Middeldorp; Elly M Hol
Journal:  Glia       Date:  2021-02-25       Impact factor: 7.452

7.  The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers.

Authors:  Holly D Soares; Maciej Gasior; Jeremy H Toyn; Jun-Sheng Wang; Quan Hong; Flora Berisha; Michael T Furlong; Joseph Raybon; Kimberley A Lentz; Francis Sweeney; Naiyu Zheng; Billy Akinsanya; Robert M Berman; Lorin A Thompson; Richard E Olson; John Morrison; Dieter M Drexler; John E Macor; Charlie F Albright; Michael K Ahlijanian; Malaz AbuTarif
Journal:  J Pharmacol Exp Ther       Date:  2016-04-20       Impact factor: 4.030

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.